{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:10:09Z","timestamp":1791382209837,"version":"4.3.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"NINDS","doi-asserted-by":"crossref","award":["NS126187"],"award-info":[{"award-number":["NS126187"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000055","name":"National Institute on Deafness and Other Communication Disorders","doi-asserted-by":"publisher","award":["DC020724"],"award-info":[{"award-number":["DC020724"]}],"id":[{"id":"10.13039\/100000055","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11060-026-05574-8","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T10:05:18Z","timestamp":1777025118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterizing the effects of anti-PD1 immunotherapy on ataxia in a vestibular schwannoma mouse model"],"prefix":"10.1007","volume":"177","author":[{"given":"Simeng","family":"Lu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Hernandez-Meadows","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenzhen","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingyu","family":"Xiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam P.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Bradley","family":"Welling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"5574_CR1","doi-asserted-by":"publisher","unstructured":"Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, Babovic-Vuksanovic D, Ferner R, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Hanemann CO, Kalamarides M, Kehrer-Sawatzki H, Korf BR, Mautner VF, MacCollin M, Papi L, Rauen KA, Riccardi V, Schorry E, Smith MJ, Stemmer-Rachamimov A, Stevenson DA, Ullrich NJ, Viskochil D, Wimmer K, Yohay K, International Consensus Group on Neurofibromatosis Diagnostic, Huson C, Wolkenstein SM, Evans P (2022) DG Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: an international consensus recommendation. Genet Med 24: 1967\u20131977 https:\/\/doi.org\/10.1016\/j.gim.2022.05.007","DOI":"10.1016\/j.gim.2022.05.007"},{"key":"5574_CR2","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1093\/neuonc\/noaa284","volume":"23","author":"C Forde","year":"2021","unstructured":"Forde C, King AT, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SR, Pathmanaban ON, Stapleton E, Thomas OM, Laitt RD, Stivaros S, Kilday JP, Vassallo G, McBain C, Kerrigan S, Smith MJ, McCabe MG, Harkness EF, Evans DG (2021) Disease course of neurofibromatosis type 2: a 30-year follow-up study of 353 patients seen at a single institution. Neuro Oncol 23:1113\u20131124. https:\/\/doi.org\/10.1093\/neuonc\/noaa284","journal-title":"Neuro Oncol"},{"key":"5574_CR3","doi-asserted-by":"publisher","unstructured":"Madhani AS, King S, Zhu J, Karmali F, Welling DB, Cai W, Jordan JT, Lewis RF (2023) Vestibular dysfunction in NF2\u2013related schwannomatosis. Brain Commun 5. https:\/\/doi.org\/10.1093\/braincomms\/fcad089","DOI":"10.1093\/braincomms\/fcad089"},{"key":"5574_CR4","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1038\/s41431-022-01086-x","volume":"30","author":"DG Evans","year":"2022","unstructured":"Evans DG, Mostaccioli S, Pang D, Fadzil OCM, Pittara M, Champollion N, Wolkenstein P, Thomas N, Ferner RE, Kalamarides M, Peyre M, Papi L, Legius E, Becerra JL, King A, Duff C, Stivaros S, Blanco I (2022) ERN GENTURIS clinical practice guidelines for the diagnosis, treatment, management and surveillance of people with schwannomatosis. Eur J Hum Genet 30:812\u2013817. https:\/\/doi.org\/10.1038\/s41431-022-01086-x","journal-title":"Eur J Hum Genet"},{"key":"5574_CR5","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/lary.27181","volume":"128","author":"KA Peng","year":"2018","unstructured":"Peng KA, Lorenz MB, Otto SR, Brackmann DE, Wilkinson EP (2018) Cochlear implantation and auditory brainstem implantation in neurofibromatosis type 2. Laryngoscope 128:2163\u20132169. https:\/\/doi.org\/10.1002\/lary.27181","journal-title":"Laryngoscope"},{"key":"5574_CR6","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1097\/00129492-200604000-00015","volume":"27","author":"TA Meyer","year":"2006","unstructured":"Meyer TA, Canty PA, Wilkinson EP, Hansen MR, Rubinstein JT, Gantz BJ (2006) Small acoustic neuromas: surgical outcomes versus observation or radiation. Otol Neurotol 27:380\u2013392. https:\/\/doi.org\/10.1097\/00129492-200604000-00015","journal-title":"Otol Neurotol"},{"key":"5574_CR7","doi-asserted-by":"publisher","unstructured":"Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG 2nd (2012) Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 33:1046\u20131052. https:\/\/doi.org\/10.1097\/MAO.0b013e31825e73f5","DOI":"10.1097\/MAO.0b013e31825e73f5"},{"key":"5574_CR8","doi-asserted-by":"publisher","first-page":"3446","DOI":"10.1200\/JCO.19.01367","volume":"37","author":"SR Plotkin","year":"2019","unstructured":"Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, Campian JL, Clapp DW, Fisher MJ, Tonsgard J, Ullrich N, Thomas C, Cutter G, Korf B, Packer R, Karajannis MA (2019) Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol 37:3446\u20133454. https:\/\/doi.org\/10.1200\/JCO.19.01367","journal-title":"J Clin Oncol"},{"key":"5574_CR9","doi-asserted-by":"publisher","unstructured":"Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E (2009) Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med 361:358\u2013367. https:\/\/doi.org\/10.1056\/NEJMoa0902579","DOI":"10.1056\/NEJMoa0902579"},{"key":"5574_CR10","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1055\/s-0038-1676628","volume":"80","author":"DE Killeen","year":"2019","unstructured":"Killeen DE, Klesse L, Tolisano AM, Hunter JB, Kutz JW Jr. (2019) Long-Term Effects of Bevacizumab on Vestibular Schwannoma Volume in Neurofibromatosis Type 2 Patients. J Neurol Surg B Skull Base 80:540\u2013546. https:\/\/doi.org\/10.1055\/s-0038-1676628","journal-title":"J Neurol Surg B Skull Base"},{"key":"5574_CR11","doi-asserted-by":"publisher","unstructured":"Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O\u2019Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C (2023) Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. N Engl J Med 388:2159\u20132170. https:\/\/doi.org\/10.1056\/NEJMoa2302312","DOI":"10.1056\/NEJMoa2302312"},{"key":"5574_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1056\/NEJMoa2202809","volume":"387","author":"J Cortes","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Perez-Garcia J, Iwata H, Masuda N, Torregroza Otero M, Gokmen E, Loi S, Guo Z, Zhou X, Karantza V, Pan W, Schmid P, Investigators K- (2022) Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 387:217\u2013226. https:\/\/doi.org\/10.1056\/NEJMoa2202809","journal-title":"N Engl J Med"},{"key":"5574_CR13","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350\u20131355","journal-title":"Science"},{"key":"5574_CR14","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/nature21349","volume":"541","author":"DS Chen","year":"2017","unstructured":"Chen DS, Mellman I (2017) Elements of cancer immunity and the cancer-immune set point. Nature 541:321\u2013330. https:\/\/doi.org\/10.1038\/nature21349","journal-title":"Nature"},{"key":"5574_CR15","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P, CheckMate I (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373:1803\u20131813. https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"key":"5574_CR16","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlhaufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crino L, Blumenschein GR Jr., Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 373:1627\u20131639. https:\/\/doi.org\/10.1056\/NEJMoa1507643","journal-title":"N Engl J Med"},{"key":"5574_CR17","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Dent R, O\u2019Shaughnessy J, Investigators K- (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 382:810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"key":"5574_CR18","doi-asserted-by":"publisher","first-page":"5023","DOI":"10.2147\/OTT.S105862","volume":"9","author":"X Wang","year":"2016","unstructured":"Wang X, Teng F, Kong L, Yu J (2016) PD-L1 expression in human cancers and its association with clinical outcomes. Onco Targets Ther 9:5023\u20135039. https:\/\/doi.org\/10.2147\/OTT.S105862","journal-title":"Onco Targets Ther"},{"key":"5574_CR19","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1038\/s41591-024-03083-7","volume":"30","author":"AJ Bullock","year":"2024","unstructured":"Bullock AJ, Schlechter BL, Fakih MG, Tsimberidou AM, Grossman JE, Gordon MS, Wilky BA, Pimentel A, Mahadevan D, Balmanoukian AS, Sanborn RE, Schwartz GK, Abou-Alfa GK, Segal NH, Bockorny B, Moser JC, Sharma S, Patel JM, Wu W, Chand D, Rosenthal K, Mednick G, Delepine C, Curiel TJ, Stebbing J, Lenz HJ, O\u2019Day SJ, El-Khoueiry AB (2024) Botensilimab plus balstilimab in relapsed\/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial. Nat Med 30:2558\u20132567. https:\/\/doi.org\/10.1038\/s41591-024-03083-7","journal-title":"Nat Med"},{"key":"5574_CR20","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1038\/s41591-023-02593-0","volume":"29","author":"JJ Luke","year":"2023","unstructured":"Luke JJ, Patel MR, Blumenschein GR, Hamilton E, Chmielowski B, Ulahannan SV, Connolly RM, Santa-Maria CA, Wang J, Bahadur SW, Weickhardt A, Asch AS, Mallesara G, Clingan P, Dlugosz-Danecka M, Tomaszewska-Kiecana M, Pylypenko H, Hamad N, Kindler HL, Sumrow BJ, Kaminker P, Chen FZ, Zhang X, Shah K, Smith DH, De Costa A, Li J, Li H, Sun J, Moore PA (2023) The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial. Nat Med 29:2814\u20132824. https:\/\/doi.org\/10.1038\/s41591-023-02593-0","journal-title":"Nat Med"},{"key":"5574_CR21","doi-asserted-by":"publisher","unstructured":"Frentzas S, Kao S, Gao R, Zheng H, Rizwan A, Budha N, de la Hoz Pedroza L, Tan W, Meniawy T (2023) AdvanTIG-105: a phase I dose escalation study of the anti-TIGIT monoclonal antibody ociperlimab in combination with tislelizumab in patients with advanced solid tumors. J Immunother Cancer 11. https:\/\/doi.org\/10.1136\/jitc-2022-005829","DOI":"10.1136\/jitc-2022-005829"},{"key":"5574_CR22","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41577-023-00973-8","volume":"24","author":"LH Butterfield","year":"2024","unstructured":"Butterfield LH, Najjar YG (2024) Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations. Nat Rev Immunol 24:399\u2013416. https:\/\/doi.org\/10.1038\/s41577-023-00973-8","journal-title":"Nat Rev Immunol"},{"key":"5574_CR23","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F Martins","year":"2019","unstructured":"Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, Shabafrouz K, Ribi C, Cairoli A, Guex-Crosier Y, Kuntzer T, Michielin O, Peters S, Coukos G, Spertini F, Thompson JA, Obeid M (2019) Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat Rev Clin Oncol 16:563\u2013580. https:\/\/doi.org\/10.1038\/s41571-019-0218-0","journal-title":"Nat Rev Clin Oncol"},{"key":"5574_CR24","doi-asserted-by":"publisher","unstructured":"Parvez MSA, Ohtsuki G (2022) Acute cerebellar inflammation and related ataxia: mechanisms and pathophysiology. Brain Sci 12. https:\/\/doi.org\/10.3390\/brainsci12030367","DOI":"10.3390\/brainsci12030367"},{"key":"5574_CR25","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1007\/s00415-014-7303-1","volume":"261","author":"RE Ferner","year":"2014","unstructured":"Ferner RE, Shaw A, Evans DG, McAleer D, Halliday D, Parry A, Raymond FL, Durie-Gair J, Hanemann CO, Hornigold R, Axon P, Golding JF (2014) Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. J Neurol 261:963\u2013969. https:\/\/doi.org\/10.1007\/s00415-014-7303-1","journal-title":"J Neurol"},{"key":"5574_CR26","doi-asserted-by":"publisher","first-page":"3483","DOI":"10.1158\/0008-5472.CAN-09-3107","volume":"70","author":"HK Wong","year":"2010","unstructured":"Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di Tomaso E (2010) Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res 70:3483\u20133493. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-3107","journal-title":"Cancer Res"},{"key":"5574_CR27","doi-asserted-by":"publisher","first-page":"14676","DOI":"10.1073\/pnas.1512570112","volume":"112","author":"X Gao","year":"2015","unstructured":"Gao X, Zhao Y, Stemmer-Rachamimov AO, Liu H, Huang P, Chin S, Selig MK, Plotkin SR, Jain RK, Xu L (2015) Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proc Natl Acad Sci U S A 112:14676\u201314681. https:\/\/doi.org\/10.1073\/pnas.1512570112","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5574_CR28","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41596-018-0105-7","volume":"14","author":"J Chen","year":"2019","unstructured":"Chen J, Landegger LD, Sun Y, Ren J, Maimon N, Wu L, Ng MR, Chen JW, Zhang N, Zhao Y, Gao X, Fujita T, Roberge S, Huang P, Jain RK, Plotkin SR, Stankovic KM, Xu L (2019) A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. Nat Protoc 14:541\u2013555. https:\/\/doi.org\/10.1038\/s41596-018-0105-7","journal-title":"Nat Protoc"},{"key":"5574_CR29","doi-asserted-by":"publisher","first-page":"E2077","DOI":"10.1073\/pnas.1719966115","volume":"115","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Liu P, Zhang N, Chen J, Landegger LD, Zhao F, Zhang J, Fujita T, Stemmer-Rachamimov AO, Zhang Y, Ferraro G, Liu H, Muzikansky A, Plotkin S, Stankovic KM, Jain RK, Xu L (2018) Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci U S A 115:E2077\u2013E2084","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5574_CR30","doi-asserted-by":"publisher","first-page":"e8316","DOI":"10.1371\/journal.pone.0008316","volume":"4","author":"E Chung","year":"2009","unstructured":"Chung E, Yamashita H, Au P, Tannous BA, Fukumura D, Jain RK (2009) Secreted Gaussia luciferase as a biomarker for monitoring tumor progression and treatment response of systemic metastases. PLoS ONE 4:e8316. https:\/\/doi.org\/10.1371\/journal.pone.0008316","journal-title":"PLoS ONE"},{"key":"5574_CR31","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nprot.2009.28","volume":"4","author":"BA Tannous","year":"2009","unstructured":"Tannous BA (2009) Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat Protoc 4:582\u2013591. https:\/\/doi.org\/10.1038\/nprot.2009.28","journal-title":"Nat Protoc"},{"key":"5574_CR32","doi-asserted-by":"publisher","first-page":"E3119","DOI":"10.1073\/pnas.1216078109","volume":"109","author":"DP Kodack","year":"2012","unstructured":"Kodack DP, Chung E, Yamashita H, Incio J, Duyverman AM, Song Y, Farrar CT, Huang Y, Ager E, Kamoun W, Goel S, Snuderl M, Lussiez A, Hiddingh L, Mahmood S, Tannous BA, Eichler AF, Fukumura D, Engelman JA, Jain RK (2012) Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc Natl Acad Sci U S A 109:E3119\u20133127. https:\/\/doi.org\/10.1073\/pnas.1216078109","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5574_CR33","doi-asserted-by":"publisher","unstructured":"Lu S, Yin Z, Chen J, Wu L, Sun Y, Gao X, Huang P, Jordan JT, Plotkin SR, Xu L (2024) Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis. Cancers (Basel) 16. https:\/\/doi.org\/10.3390\/cancers16111961","DOI":"10.3390\/cancers16111961"},{"key":"5574_CR34","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1200\/JCO.2008.19.9356","volume":"27","author":"WS Kamoun","year":"2009","unstructured":"Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK (2009) Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice. J Clin Oncol 27:2542\u20132552. https:\/\/doi.org\/10.1200\/JCO.2008.19.9356","journal-title":"J Clin Oncol"},{"key":"5574_CR35","doi-asserted-by":"publisher","unstructured":"Wu L, Vasilijic S, Sun Y, Chen J, Landegger LD, Zhang Y, Zhou W, Ren J, Early S, Yin Z, Ho WW, Zhang N, Gao X, Lee GY, Datta M, Sagers JE, Brown A, Muzikansky A, Stemmer-Rachamimov A, Zhang L, Plotkin SR, Jain RK, Stankovic KM, Xu L (2021) Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. Sci Transl Med 13. https:\/\/doi.org\/10.1126\/scitranslmed.abd4816","DOI":"10.1126\/scitranslmed.abd4816"},{"key":"5574_CR36","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550. https:\/\/doi.org\/10.1186\/s13059-014-0550-8","journal-title":"Genome Biol"},{"key":"5574_CR37","doi-asserted-by":"publisher","first-page":"7905","DOI":"10.1158\/0008-5472.CAN-09-2099","volume":"69","author":"L Xu","year":"2009","unstructured":"Xu L, Duda DG, di Tomaso E, Ancukiewicz M, Chung DC, Lauwers GY, Samuel R, Shellito P, Czito BG, Lin PC, Poleski M, Bentley R, Clark JW, Willett CG, Jain RK (2009) Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 69:7905\u20137910. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2099","journal-title":"Cancer Res"},{"key":"5574_CR38","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1073\/pnas.1818357116","volume":"116","author":"Y Zhao","year":"2019","unstructured":"Zhao Y, Cao J, Melamed A, Worley M, Gockley A, Jones D, Nia HT, Zhang Y, Stylianopoulos T, Kumar AS, Mpekris F, Datta M, Sun Y, Wu L, Gao X, Yeku O, Del Carmen MG, Spriggs DR, Jain RK, Xu L (2019) Losartan treatment enhances chemotherapy efficacy and reduces ascites in ovarian cancer models by normalizing the tumor stroma. Proc Natl Acad Sci U S A 116:2210\u20132219. https:\/\/doi.org\/10.1073\/pnas.1818357116","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5574_CR39","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1158\/1078-0432.ccr-0953-03","volume":"10","author":"L Xu","year":"2004","unstructured":"Xu L, Pathak PS, Fukumura D (2004) Hypoxia-induced activation of p38 mitogen-activated protein kinase and phosphatidylinositol 3\u2019-kinase signaling pathways contributes to expression of interleukin 8 in human ovarian carcinoma cells. Clin Cancer Res 10:701\u2013707. https:\/\/doi.org\/10.1158\/1078-0432.ccr-0953-03","journal-title":"Clin Cancer Res"},{"key":"5574_CR40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1158\/2326-6066.CIR-15-0151","volume":"4","author":"DA Reardon","year":"2016","unstructured":"Reardon DA, Gokhale PC, Klein SR, Ligon KL, Rodig SJ, Ramkissoon SH, Jones KL, Conway AS, Liao X, Zhou J, Wen PY, Van Den Abbeele AD, Hodi FS, Qin L, Kohl NE, Sharpe AH, Dranoff G, Freeman GJ (2016) Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunol Res 4:124\u2013135. https:\/\/doi.org\/10.1158\/2326-6066.CIR-15-0151","journal-title":"Cancer Immunol Res"},{"key":"5574_CR41","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","volume":"19","author":"DB Johnson","year":"2022","unstructured":"Johnson DB, Nebhan CA, Moslehi JJ, Balko JM (2022) Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 19:254\u2013267. https:\/\/doi.org\/10.1038\/s41571-022-00600-w","journal-title":"Nat Rev Clin Oncol"},{"key":"5574_CR42","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","volume":"29","author":"J Mahdi","year":"2023","unstructured":"Mahdi J, Dietrich J, Straathof K, Roddie C, Scott BJ, Davidson TB, Prolo LM, Batchelor TT, Campen CJ, Davis KL, Gust J, Lim M, Majzner RG, Park JR, Partap S, Ramakrishna S, Richards R, Schultz L, Vitanza NA, Wang LD, Mackall CL, Monje M (2023) Tumor inflammation-associated neurotoxicity. Nat Med 29:803\u2013810. https:\/\/doi.org\/10.1038\/s41591-023-02276-w","journal-title":"Nat Med"},{"key":"5574_CR43","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s12276-020-0445-6","volume":"52","author":"NA Sims","year":"2020","unstructured":"Sims NA (2020) The JAK1\/STAT3\/SOCS3 axis in bone development, physiology, and pathology. Exp Mol Med 52:1185\u20131197. https:\/\/doi.org\/10.1038\/s12276-020-0445-6","journal-title":"Exp Mol Med"},{"key":"5574_CR44","doi-asserted-by":"publisher","first-page":"e200287","DOI":"10.1212\/NXI.0000000000200287","volume":"11","author":"A Farina","year":"2024","unstructured":"Farina A, Villagran-Garcia M, Benaiteau M, Lamblin F, Fourier A, Honnorat J, Joubert B (2024) Opsoclonus-Ataxia Syndrome in a Patient With Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors. Neurol Neuroimmunol Neuroinflamm 11:e200287. https:\/\/doi.org\/10.1212\/NXI.0000000000200287","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"5574_CR45","doi-asserted-by":"publisher","unstructured":"Kooshkaki O, Derakhshani A, Hosseinkhani N, Torabi M, Safaei S, Brunetti O, Racanelli V, Silvestris N, Baradaran B (2020) Combination of ipilimumab and nivolumab in cancers: from clinical practice to ongoing clinical trials. Int J Mol Sci 21. https:\/\/doi.org\/10.3390\/ijms21124427","DOI":"10.3390\/ijms21124427"},{"key":"5574_CR46","doi-asserted-by":"publisher","unstructured":"Kouzel Martinez F, Graffeo CS, Carlstrom LP, Link MJ (2021) Growth arrest of a refractory vestibular schwannoma after anti-PD-1 antibody treatment. BMJ Case Rep 14. https:\/\/doi.org\/10.1136\/bcr-2021-241834","DOI":"10.1136\/bcr-2021-241834"},{"key":"5574_CR47","doi-asserted-by":"publisher","first-page":"e2202719119","DOI":"10.1073\/pnas.2202719119","volume":"119","author":"SG Ahmed","year":"2022","unstructured":"Ahmed SG, Oliva G, Shao M, Wang X, Mekalanos JJ, Brenner GJ (2022) Intratumoral injection of schwannoma with attenuated Salmonella typhimurium induces antitumor immunity and controls tumor growth. Proc Natl Acad Sci U S A 119:e2202719119. https:\/\/doi.org\/10.1073\/pnas.2202719119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5574_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","volume":"73","author":"S Cuzzubbo","year":"2017","unstructured":"Cuzzubbo S, Javeri F, Tissier M, Roumi A, Barlog C, Doridam J, Lebbe C, Belin C, Ursu R, Carpentier AF (2017) Neurological adverse events associated with immune checkpoint inhibitors: Review of the literature. Eur J Cancer 73:1\u20138. https:\/\/doi.org\/10.1016\/j.ejca.2016.12.001","journal-title":"Eur J Cancer"},{"key":"5574_CR49","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","volume":"87","author":"D Dubey","year":"2020","unstructured":"Dubey D, David WS, Reynolds KL, Chute DF, Clement NF, Cohen JV, Lawrence DP, Mooradian MJ, Sullivan RJ, Guidon AC (2020) Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Ann Neurol 87:659\u2013669. https:\/\/doi.org\/10.1002\/ana.25708","journal-title":"Ann Neurol"},{"key":"5574_CR50","doi-asserted-by":"publisher","unstructured":"(2021) Correction: Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer 9:1 https:\/\/doi.org\/10.1136\/jitc-2021-002890corr1","DOI":"10.1136\/jitc-2021-002890corr1"},{"key":"5574_CR51","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A Marini","year":"2021","unstructured":"Marini A, Bernardini A, Gigli GL, Valente M, Muniz-Castrillo S, Honnorat J, Vogrig A (2021) Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Neurology 96:754\u2013766. https:\/\/doi.org\/10.1212\/WNL.0000000000011795","journal-title":"Neurology"},{"key":"5574_CR52","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1007\/s12311-024-01727-5","volume":"23","author":"M Dentoni","year":"2024","unstructured":"Dentoni M, Florean I, Farina A, Joubert B, Do LD, Honnorat J, Damato V, Fabris M, Gigli GL, Valente M, Vogrig A (2024) Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia. Cerebellum 23:2308\u20132323. https:\/\/doi.org\/10.1007\/s12311-024-01727-5","journal-title":"Cerebellum"},{"key":"5574_CR53","doi-asserted-by":"publisher","first-page":"3373","DOI":"10.1021\/acs.jctc.9b00541","volume":"16","author":"PK Tang","year":"2020","unstructured":"Tang PK, Chakraborty K, Hu W, Kang M, Loverde SM (2020) Interaction of Camptothecin with Model Cellular Membranes. J Chem Theory Comput 16:3373\u20133384. https:\/\/doi.org\/10.1021\/acs.jctc.9b00541","journal-title":"J Chem Theory Comput"},{"key":"5574_CR54","doi-asserted-by":"publisher","first-page":"774170","DOI":"10.3389\/fphar.2022.774170","volume":"13","author":"V Albarran","year":"2022","unstructured":"Albarran V, Chamorro J, Rosero DI, Saavedra C, Soria A, Carrato A, Gajate P (2022) Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature. Front Pharmacol 13:774170. https:\/\/doi.org\/10.3389\/fphar.2022.774170","journal-title":"Front Pharmacol"},{"key":"5574_CR55","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1097\/WCO.0000000000000391","volume":"29","author":"AF Hottinger","year":"2016","unstructured":"Hottinger AF (2016) Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 29:806\u2013812. https:\/\/doi.org\/10.1097\/WCO.0000000000000391","journal-title":"Curr Opin Neurol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05574-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-026-05574-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-026-05574-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:59:33Z","timestamp":1779782373000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-026-05574-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":55,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["5574"],"URL":"https:\/\/doi.org\/10.1007\/s11060-026-05574-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by MGH\u2019s Institutional Animal Care and Use Committee (Protocol #2016N00004).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"120"}}